相关临床试验
9
1 进行中
药物批准
2
批准总数
监管机构
1
监管机构数
成立时间
N/A
已完成
6
66.7%
尚未招募
1
11.1%
招募中
2
22.2%
- Verrica Pharmaceuticals announced the first U.S. patient has been dosed in the COVE-3 pivotal Phase 3 trial evaluating YCANTH (VP-102) for the treatment of common warts. - Development partner Torii Pharmaceutical simultaneously dosed the first Japanese patient in the same COVE-3 study, marking a key milestone in the global Phase 3 program. - Common warts affect an estimated 22 million people in the U.S. alone with no FDA-approved therapies, representing one of the largest unmet needs in dermatology. - The Phase 2 COVE-1 trial showed 51% of subjects achieved complete clearance of all treatable warts at Day 84 with no serious adverse events observed.
- Verrica Pharmaceuticals' VP-315 demonstrated a potential abscopal effect in Phase 2 trials, with untreated basal cell carcinoma lesions showing a 67% reduction in size following treatment of separate target lesions. - The oncolytic peptide immunotherapy achieved complete histologic clearance in 21% of non-treated lesions, suggesting broader immune activation beyond the injection site. - Results indicate VP-315 could address the significant unmet need for patients with multiple BCC lesions, as approximately one-third of patients develop additional primary tumors over their lifetime. - The therapy reduced overall tumor size by an average of 86% in treated lesions, potentially improving patient outcomes by reducing the complexity of future surgical procedures.
- Verrica Pharmaceuticals dosed the first patient in December 2025 for a global Phase 3 trial evaluating VP-102 for common warts, a condition affecting approximately 22 million people in the United States. - The Phase 3 program is supported by Phase 2 COVE-1 trial results showing 51% of patients achieved complete wart clearance at day 84, with no serious adverse events reported. - VP-102 could become the first FDA-approved therapy specifically for common warts, addressing a significant unmet medical need in dermatology with potential multibillion-dollar market opportunity. - Torii Pharmaceutical will share development costs 50/50 and fund the first $40 million of trial expenses, representing approximately 90% of the current projected trial budget.
- Verrica Pharmaceuticals raised approximately $50 million through a private placement financing to retire debt and extend operations into mid-2027. - The company will use $35 million to fully repay OrbiMed debt obligations, eliminating restrictive covenants and interest payments. - Financing enables advancement of VP-315 Phase 3 trials for basal cell carcinoma and global Phase 3 program for common warts starting before end of 2025. - YCANTH remains the only FDA-approved treatment for molluscum contagiosum, affecting approximately 6 million Americans primarily children.
- The European Medicines Agency's Committee for Medicinal Products for Human Use concluded that existing Phase 3 data from U.S. and Japan studies are sufficient to support YCANTH's approval in Europe for molluscum contagiosum treatment. - YCANTH is the first and only FDA-approved healthcare professional-administered treatment for molluscum contagiosum, affecting an estimated six million people in the United States primarily children. - Verrica plans to file the Marketing Authorization Application as early as Q4 2026, targeting the significant unmet medical need in the European molluscum market. - The regulatory feedback provides alignment on study design acceptability, clinical safety data requirements, and adequacy of nonclinical studies for the European filing.
- Verrica Pharmaceuticals will present new data on VP-315, its oncolytic peptide therapy for basal cell carcinoma, at the Society for Immunotherapy of Cancer 40th Annual Meeting in November 2025. - The presentation will focus on exploratory analysis of local immune activation in the tumor microenvironment 12 weeks post-treatment with VP-315 from a Phase 2 multicenter study. - VP-315 is a potential first-in-class oncolytic chemotherapeutic peptide immunotherapy that induces immunogenic cell death and unleashes tumor antigens for T cell responses, offering a non-surgical treatment option. - The therapy has demonstrated positive tumor-specific immune cell responses in multi-indication Phase 1/2 oncology trials and is based on pioneering research in host defense peptides.
- Over 22 pharmaceutical companies are actively developing 25+ pipeline drugs for basal cell neoplasms, the most common type of skin cancer characterized by slow growth and low metastatic potential. - Recent clinical milestones include Senhwa Biosciences completing Phase I trials for Silmitasertib with positive survival outcomes, and multiple companies reporting positive Phase II results for their respective candidates. - Leading late-stage candidates include Sol-Gel Technologies' Patidegib, a first-in-class topical hedgehog pathway inhibitor targeting Gorlin Syndrome and basal cell carcinomas. - The pipeline features diverse mechanisms of action including SMO protein inhibitors, tyrosine kinase inhibitors, and casein kinase II inhibitors, addressing the growing demand driven by rising UV exposure and aging populations.
- Verrica Pharmaceuticals has initiated a global Phase 3 clinical trial for YCANTH to treat common warts, a condition affecting approximately 22 million patients in the United States with no FDA-approved prescription therapies currently available. - The company will receive up to $18 million in milestone payments from partner Torii Pharmaceutical, including an accelerated $8 million payment in July 2025 and a potential $10 million payment upon Japanese approval for molluscum contagiosum. - Torii will fund the first $40 million of trial costs, representing approximately 90% of the current clinical budget, while Verrica maintains global rights to YCANTH outside of Japan. - The first patient dosing in the US Phase 3 trial is expected in the fourth quarter of 2025, potentially expanding YCANTH's label to address what the company describes as the largest remaining unmet need in medical dermatology.
- Verrica Pharmaceuticals achieved a milestone with over 10,000 YCANTH® dispensed applicator units in Q1 2025, representing a 16.7% sequential increase from the previous quarter. - The company reports normalized distribution inventory levels, indicating that dispensed units will now more closely track actual demand and gross revenue. - Following a commercial restructuring, Verrica is positioned for sustainable revenue growth as it works to establish YCANTH® as the standard of care for molluscum contagiosum.
- The global basal cell carcinoma market is projected to grow from $5.48 billion in 2024 to $9.7 billion by 2035, exhibiting a CAGR of 5.34% according to IMARC Group research. - Increased public awareness, improved diagnostic technologies, and a growing preference for non-invasive treatment options are key factors driving market expansion. - Novel therapies including hedgehog pathway inhibitors and immunotherapies are transforming treatment approaches, with companies like Verrica Pharmaceuticals and AiViva BioPharma advancing promising pipeline candidates.
